WATERTOWN, Mass.–(BUSINESS WIRE)–pSivida CEO invited to speak at Surfaces in BioMaterials Foundation’s BioInterface 2015 Annual symposium in Scottsdale September 21-23
Resumen: Salutaris Medical Devices obtiene la autorización 510(k)
BARCELONA, España–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD®) ha anunciado en el Ophthalmology Futures European Forum 2015 que su fuente braquiterápica y de radionúclidos SMD Sr90-1 ha recibido la autorización 510(k) de la Administración de Alimentos y Medicamentos de EE. UU. La SMD Sr90-1 RBS está indicada para la braquiterapia episcleral de tumores y crecimientos benignos y diseñada para usarse con sistemas de aplicación de braquiterapia manuales. Laurence Marsteller, CEO de Sa
Samenvatting: Salutaris Medical Devices krijgt 510(k)-vergunning
BARCELONA, Spanje–(BUSINESS WIRE)–Salutaris Medical Devices (SalutarisMD ®) heeft op het Ophthalmology Futures European Forum 2015 bekendgemaakt dat zijn SMD Sr90-1 Radionuclide Brachytherapy Source (RBS) een 510(k)-autorisatie heeft gekregen van de Amerikaanse Food and Drug Administration (FDA). De SMD Sr90-1 RBS is bedoeld voor inwendige episclerale bestraling van tumoren of goedaardige groei. Het dient te worden toegepast in een handmatig bestuurbaar systeem voor inwendige bestraling. Laur
ACADIA Pharmaceuticals Appoints Steve Davis as Chief Executive Officer
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced that its Board of Directors has appointed Steve Davis as President and Chief Executive Officer. Mr. Davis has been serving as ACADIA’s Interim Chief Executive Officer since March 2015. Mr. Davis has also been appointed to the ACADIA Board of
NovaBay Pharmaceuticals to Present at Rodman & Renshaw Global Investment Conference
EMERYVILLE, Calif.–(BUSINESS WIRE)–NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing novel topical non-antibiotic antimicrobial products for the global eye care market, announces that President and CEO Ron Najafi, Ph.D., will present at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10, 2015 at 3:25 p.m. Eastern time (12:25 p.m. Pacific time). The conference is being held at the St. Regis Hotel
ACADIA Pharmaceuticals Submits New Drug Application for NUPLAZID™ for the Treatment of Parkinson’s Disease Psychosis
SAN DIEGO–(BUSINESS WIRE)–ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders, today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for NUPLAZID™ (pimavanserin) for the treatment of psychosis associated with Parkinson’s disease. NUPLAZID is an SSIA (selective sero